Beam Therapeutics vs Ginkgo Bioworks
BEAM and DNA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BEAM and DNA compare
Beam Therapeutics is the larger company, worth 3.6 times as much as Ginkgo Bioworks ($2.4B against $647M).
Beam Therapeutics grew revenue faster over the last twelve months (159% versus −13.2% for Ginkgo Bioworks).
Beam Therapeutics keeps more of each dollar of sales as profit, with a net margin of −54.7% compared with −192% at Ginkgo Bioworks.
Ginkgo Bioworks scores higher on the StockData Score (9 against 7 for Beam Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BEAM | DNA |
|---|---|---|
| Size and price | ||
| Market cap | $2.4B | $647M |
| Share price | $22.83 | $9.61 |
| Change, 1 year | 4.4% | 15.0% |
| Change, 5 years | −74.6% | −98.2% |
| Beta (5Y) | 1.99 | 2.73 |
| Employees | 511 | 485 |
| StockData Score | ||
| Total score | 7 | 9 (better) |
| Valuation score | 1 | 2 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 2 | 2 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 15.1× | 4.9× (better) |
| P/B | 2.2× | 1.6× (better) |
| FCF yield | −15.8% (better) | −26.8% |
| Fair value | $23.90 | $9.67 |
| Margin of safety | 4.5% (better) | 0.61% |
| Growth | ||
| Revenue growth (TTM) | 159% (better) | −13.2% |
| Revenue growth, 5Y average | 466% (better) | 17.3% |
| Profitability | ||
| Operating margin | −242% | −205% (better) |
| Net margin | −54.7% (better) | −192% |
| FCF margin | −239% | −133% (better) |
| Return on equity | −8.1% (better) | −52.7% |
| Return on invested capital | – | −113% |
| Financial health | ||
| Debt / equity | 0.09 (better) | 0.00 |
| Current ratio | 14.57 (better) | 4.72 |
| Altman Z-score | 2.72 (better) | −9.15 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 106% | 53.7% |
| Held by insiders | 3.4% | – |
| Insider net buying, 12 months | −$19.7M | −$5.0M (better) |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 26.1% | – |
Go deeper
- BEAM stock overview
- BEAM income statement
- BEAM valuation and score
- DNA stock overview
- DNA income statement
- DNA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.